Annual report
7733.TEDINET S100W009
Period2024-04-01 → 2025-03-31
Filed2025-06-19
StandardIFRS
ConsolidatedYes
Data checks19 of 19 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥997.3bn | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥925.8bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥881.9bn | 2022-04-01 → 2023-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥750.1bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥730.5bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥162.5bn | 2024-04-01 → 2025-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥51.4bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥159.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥43.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥182.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥141.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥76.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥117.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥242.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥143.4bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥117.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥242.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.43T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.53T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.51T | at 2023-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.36T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.18T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥681.1bn | at 2025-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥777.0bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥751.7bn | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥757.2bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥751.7bn | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥757.2bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥640.1bn | at 2023-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥510.2bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥394.3bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥252.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥340.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.5bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥302.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥217.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥190.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥42.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥98.5bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥124.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥65.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥360.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥58.4bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥118.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥211.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥276.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥143.2bn | 2022-04-01 → 2023-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥40.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥102.99 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥199.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.22 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥10.05 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥102.8 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥199.44 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.08 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥10.04 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥666.54 | at 2025-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥649.59 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥510.62 | at 2023-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥400.75 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥306.72 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 52.5% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 49.4% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 42.4% | at 2023-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 33.3% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 15.6% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 34.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 24.9% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 25.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.4% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 29,297 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 28,838 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 32,805 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 31,557 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 31,653 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥389.8bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥379.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥380.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥378.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥344.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥12.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥41.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥69.5bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥135.1bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥152.3bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥57.2bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥49.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥70.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥382.1bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥61.7bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥293.6bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥130.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥84.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥8.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥913.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥954.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥973.6bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥900.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥826.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥455.8bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥442.0bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥457.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥512.9bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥418.3bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥357.2bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥349.8bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥112.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥190.1bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥53.89 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥241.97 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.88 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.13 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.64 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥53.79 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥241.41 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥102.76 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.1 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.64 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥18 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥405.22 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥439.81 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥333.48 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥280.3 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥271.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 50.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.9% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.6% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 12.7% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 63.1% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 33.6% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 24.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,139,116,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,215,147,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,266,179,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,299,294,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,494 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 2,834 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 2,727 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 3,478 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,775 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 26 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥5.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | −¥473m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥280.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥39.9bn |
| Endoscopicreportable segment | employees | at 2025-03-31 | 16139 pure |
| Endoscopic Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥56.5bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2025-03-31 | ¥672.5bn |
| Endoscopic Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥141.4bn |
| Therapeuticreportable segment | employees | at 2025-03-31 | 8399 pure |
| Therapeutic Solutionsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥21.6bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2025-03-31 | ¥474.5bn |
| Therapeutic Solutionsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥61.5bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥78.1bn |
| —segment total | segment assets | at 2025-03-31 | ¥1.15T |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥202.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥50m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥3.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | −¥287m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥9.3bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥424.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥44.5bn |
| Endoscopic Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥50.7bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2024-03-31 | ¥637.0bn |
| Endoscopic Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥104.7bn |
| Therapeutic Solutionsreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥19.3bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2024-03-31 | ¥469.2bn |
| Therapeutic Solutionsreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥8.5bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥70.0bn |
| —segment total | segment assets | at 2024-03-31 | ¥1.11T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥96.2bn |
| Endoscopicreportable segment | employees | at 2025-03-31 | 963 pure |
| Therapeuticreportable segment | employees | at 2025-03-31 | 331 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,960
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in retirement benefit asset ope cf IFRS | CurrentYearDuration | -1197000000 | JPY |
| Increase decrease in provisions ope cf IFRS | Prior1YearDuration | 9083000000 | JPY |
| Increase decrease in provisions ope cf IFRS | CurrentYearDuration | -15225000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YearDuration | 43221000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYearDuration | 6338000000 | JPY |
| Subtotal ope cf IFRS | Prior1YearDuration | 182182000000 | JPY |
| Subtotal ope cf IFRS | CurrentYearDuration | 188340000000 | JPY |
| Interest received ope cf IFRS | Prior1YearDuration | 2365000000 | JPY |
| Interest received ope cf IFRS | CurrentYearDuration | 3296000000 | JPY |
| Dividends received ope cf IFRS | Prior1YearDuration | 11000000 | JPY |
| Dividends received ope cf IFRS | CurrentYearDuration | 12000000 | JPY |
| Interest paid ope cf IFRS | Prior1YearDuration | -4803000000 | JPY |
| Interest paid ope cf IFRS | CurrentYearDuration | -4194000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YearDuration | -137390000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYearDuration | 3009000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YearDuration | 42365000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYearDuration | 190463000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YearDuration | -46425000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYearDuration | -46001000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YearDuration | -18199000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYearDuration | -19208000000 | JPY |
| Purchase of investment securities inv cf IFRS | Prior1YearDuration | -28000000 | JPY |
| Purchase of investment securities inv cf IFRS | CurrentYearDuration | -8588000000 | JPY |
| Proceeds from sale of ssd business inv cf IFRS | Prior1YearDuration | 379091000000 | JPY |
| Proceeds from sale of ssd business inv cf IFRS | CurrentYearDuration | － | JPY |
| Proceeds from transfer of collagen business and dental product sales businesses inv cf IFRS | Prior1YearDuration | 1656000000 | JPY |
| Proceeds from transfer of collagen business and dental product sales businesses inv cf IFRS | CurrentYearDuration | － | JPY |
| Proceeds from transfer of orthopedic surgery business inv cf IFRS | Prior1YearDuration | － | JPY |
| Proceeds from transfer of orthopedic surgery business inv cf IFRS | CurrentYearDuration | 3730000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YearDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYearDuration | -3881000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | Prior1YearDuration | 4472000000 | JPY |
| Proceeds from sale of subsidiaries inv cf IFRS | CurrentYearDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YearDuration | 53373000000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYearDuration | 4283000000 | JPY |
| Payments for contingent consideration inv cf IFRS | Prior1YearDuration | -2966000000 | JPY |
| Payments for contingent consideration inv cf IFRS | CurrentYearDuration | -4793000000 | JPY |
| Expenditure based on stock acquisition agreements inv cf IFRS | Prior1YearDuration | -43647000000 | JPY |
| Expenditure based on stock acquisition agreements inv cf IFRS | CurrentYearDuration | － | JPY |
| Claw back from cancellation of stock acquisition agreements inv cf IFRS | Prior1YearDuration | 31110000000 | JPY |
| Claw back from cancellation of stock acquisition agreements inv cf IFRS | CurrentYearDuration | 7603000000 | JPY |
| Other inv cf IFRS | Prior1YearDuration | 1555000000 | JPY |
| Other inv cf IFRS | CurrentYearDuration | 1386000000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YearDuration | 359992000000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYearDuration | -65469000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1YearDuration | -19518000000 | JPY |
| Repayments of lease obligations fin cf IFRS | CurrentYearDuration | -19302000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YearDuration | -40000000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYearDuration | -50035000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YearDuration | -20057000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 19 of 19 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |